期刊文献+

前列腺癌患者10号染色体杂合性缺失与骨转移关系的初步研究 被引量:1

Loss of Heterozygosity on Chromosome 10 Is Associated with Bone Metastasis of Human Prostate Cancer
下载PDF
导出
摘要 目的:探讨人前列腺癌特异性骨转移的细胞遗传学机制。方法:应用比较基因组杂交技术对18例前列腺癌患者进行染色体变异情况的初步分析,确定可能与骨转移密切相关的变异染色体。再应用PCR及微卫星多态性技术重点对10号染色体上的7个微卫星位点进行杂合性缺失(LOH)检测。结果:11例伴有远处骨转移的患者组织样本中,10号染色体的变异率为90.9%(10/11),显著高于其他染色体(P<0.01);进一步分析发现,7个微卫星位点的LOH现象中,骨转移患者的发生率最高,且以D10S1693~D10S587(10q24.2~q25.3)区的LOH发生率最高。结论:10号染色体上D10S1693~D10S587区(10q24.2~q25.3)是前列腺癌骨转移患者中一个高频的LOH区,此区可能与前列腺癌患者远处骨转移的发生密切相关。 Objective : To study the cytogenetic mechanism of bone metastasis of human prostate cancer (PCa). Methods: We analyzed chromosome variation by comparative genomic hybridization in 18 patients with prostate cancer to determine the chromosome vari- ants associated with bone metastasis, and focused on 7 mierosatellite sites on chromosome 10 for the detection of the loss of heterozygosity (LOH) by PCR-based microsatellite polymorphism analysis. Results: In the 11 samples with bone metastasis, the variation rate of chromosome 10 was 90.9% ( 10/11 ), significantly higher than that of the others ( P 〈 0.01 ). A much higher LOH frequency was observed at the 7 microsatellite loci on chromosome 10 and the highest located in 10q24.2-q25.3 ( D10SI693-D10S587 ) in the PCa patients with bone metastasis. Conclusion : There is a high-frequency LOH region in 10q24.2-q25.3 ( D10S1693-D10S587 ) on chromosome 10 in PCa patients with bone metastasis, which may be potentially involved in PCa progression and specific bone metastasis. Natl J Androl, 2008, 14 (10) : 879-883
出处 《中华男科学杂志》 CAS CSCD 2008年第10期879-883,共5页 National Journal of Andrology
基金 北京市科干局科研基金
关键词 前列腺癌 骨转移 染色体 杂合性缺失 prostate cancer bone metastasis chromosome loss of heterozygosity
  • 相关文献

参考文献17

  • 1Jee KJ, Kim YT, Kim KR, et al. Loss in 3p and 4p and gain of 3q are concomitant aberrations in Squamous cell carcinoma of the vulva [J]. Mod Pathol, 2001, 14(5) : 377-381.
  • 2Verma RS, Manikal M, Conte RA, et al. Chromosomal basis of adenocarcinoma of the prostate [J]. Cancer Invest, 1999, 17 (6) : 441-447.
  • 3Karma D, Lin MF, Johansson SL, et al. Current status of the molecular genetics of human prostatic adenocarcinomas [ J ]. Int J Cancer, 2003, 103(3) : 285-293.
  • 4Washburn JG, Wojno KJ, Dey J, et al. 8pter-p23 deletion is associated with racial differences in prostate cancer outcome [ J ]. Clin Cancer Res, 2000, 6(12): 4647-4652.
  • 5Oba K, Matsuyama H, Yoshihiro S, et al. Two putative tumor suppressor genes on chromosome arm 8p may play different roles in prostate cancer [ J]. Cancer Genet Cytogenet, 2001, 124( 1 ) : 20-26.
  • 6Bova GS, MacGrogan D, Levy A, et al. Physical mapping of chromosome 8p22 markers and their homozygous deletion in a metastatic prostate cancer [J]. Genomics, 1996, 35(1 ): 46-54.
  • 7Saric T, Brkanac Z, Troyer DA, et al. Genetic pattern of prostate cancer progression [J]. Int J cancer, 1999, 81 (2) : 219-224.
  • 8Suzuki H, Freije D, Nusskern DR, et al. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues [J]. Cancer Res, 1998, 58(2) : 204-209.
  • 9Vlietstra RJ, van alewijk DC, Herman KG, et al. Frequent inactivation of PTEN in prostate cancer cell lines arid xenografts [ J ]. Cancer Res, 1998, 58 (13) : 2720-2723.
  • 10Rubin MA, Gerstein A, Reid K, et al. 10q23.3 loss of heterozygosity is higher in lymph node positive (pT2-3, N^ + ) versus lymph node negative ( pT2-3, NO ) prostate cancer[J]. Hum Pathol, 2000, 31(4): 504-508.

二级参考文献1

共引文献1

同被引文献10

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部